
    
      FIH, Phase 1, open-label, multi centre, non randomised study of CB307, a trispecific
      HumabodyÂ® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours.
      The study will consist of a dose escalation and cohort expansion. Up to 50 patients will
      participate. Patients will receive CB307 IV, until loss of clinical benefit, unacceptable
      toxicity or end of study. The dose escalation may be adapted by the SRC based on clinical
      experience and safety review.
    
  